HRAS and hereditary pheochromocytoma-paraganglioma: The study showed that relatively few cancers harbor HRAS mutations, particularly thyroid cancer, pheochromocytoma and paraganglioma, and HNSCC, with HNSCC expressing the highest levels of HRAS transcripts.